AstraZeneca said it will acquire U.K. biotech company Arrow Therapeutics for $150 million to boost research on bacteria and virus compounds, a day after announcing two licensing agreements worth $800 million to develop obesity and respiratory drugs. The drugmaker also announced plans to cut 3,000 jobs.

Full Story:
Bloomberg, Reuters

Related Summaries